FDLI Annual Enforcement, Litigation & Compliance Conference - Unique Compliance & Enforcement Issues with Cell and Gene Therapies
Dec 12 2018
On Wednesday, December 12, Barbara Binzak Blumenfeld, shareholder in the firm's FDA & Biotechnology practice, will participate in a panel discussion at the Food and Drug Law Institute’s (FDLI’s) annual Enforcement, Litigation and Compliance Conference in Washington DC. The panel, “Unique Compliance and Enforcement Issues with Cell and Gene Therapies,” will discuss how FDA can foster innovation in the cell and gene therapy sectors while also ensuring that manufacturers of these novel products comply with the appropriate FDA statutory and regulatory authorities. Barbara will specifically address recent enforcement actions against stem cell companies by FDA, DOJ and FTC.